Who
Louise Rodino-Klapac
President, R&D and Tech Ops
Company insider
Files Form 4 as: President, R&D and Tech Ops, Sarepta Therapeutics.
In numbers
- Trades disclosed
- 65
- Buys
- 1
- Sells
- 0
- Bought
- $300K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 14 Dec 2020
- Last trade
- 4 Sep 2026
- Last filed
- 8 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 4 Sep 2026filed 8 Sep 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $476K21,423 at $22.22 | filing |
| 4 Sep 2026filed 8 Sep 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $476K21,423 at $22.22 | filing |
| 11 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K948 at $17.03 | filing |
| 11 Mar 2026filed 13 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $16K948 at $17.03 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,543504 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K895 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $8,543504 at $16.95 | filing |
| 9 Mar 2026filed 11 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $15K895 at $16.95 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $60K3,718 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K767 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $60K3,718 at $16.20 | filing |
| 2 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $12K767 at $16.20 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | —8,125 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —8,125 at $0.00 | filing |
| 1 Mar 2026filed 3 Mar 2026 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code M | —8,125 | filing |
| 25 Feb 2026filed 27 Feb 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,875 | filing |
| 25 Feb 2026filed 27 Feb 2026 | SRPT Sarepta Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,875 | filing |
| 17 Nov 2025filed 19 Nov 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code F | $84K4,582 at $18.42 | filing |
| 3 Sep 2025filed 5 Sep 2025 | SRPT Sarepta TherapeuticsBiotechnology | SEC FORM 4 Code A | —93,875 at $0.00 | filing |
News
Contrasting Sarepta Therapeutics (NASDAQ:SRPT) & AbCellera Biologics (NASDAQ:ABCL)SRPT · tickerreport.com · 11 Oct 2026
0 headlines in the last 90 days name Louise Rodino-Klapac; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.